A Randomized Phase II Study of LAZE rtiNib Alone Versus Lazertinib Plus bevaCizumab for NSCLC With EGFR + & Smoker

NCT06156527 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

120

Enrollment

OTHER_GOV

Sponsor class

Conditions

Lazertinib

Interventions

DRUG: Lazertinib
DRUG: Bevacizumab Injectable Product

Sponsor

National Cancer Center, Korea